Medyi Liquid Wart Corn Remover

Description

No description information is available for the drug.

Uses and Indications

This drug is indicated for the removal of common warts and plantar warts.

There are no teratogenic effects associated with this drug. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The affected area should be washed thoroughly prior to treatment. It is recommended to soak the wart in warm water for approximately 5 minutes to facilitate the application process. After soaking, the area must be dried completely.

Using a cotton swab, a sufficient amount of the medication should be applied to ensure complete coverage of each wart. Following application, the treated area should be allowed to dry.

This procedure may be repeated once or twice daily as needed, continuing until the wart is removed, for a maximum duration of 12 weeks.

Contraindications

Use is contraindicated in the following situations:

Application on irritated skin or any area that is infected or reddened is prohibited due to the potential for exacerbating the condition.

The product should not be applied to moles, birthmarks, warts with hair growth, genital warts, or warts located on the face or mucous membranes, as these areas may have increased sensitivity or risk of adverse reactions.

Additionally, individuals with diabetes or poor blood circulation should avoid use, as these conditions may impair healing and increase the risk of complications.

Warnings and Precautions

For external use only. This product is contraindicated for application on irritated skin or any area that exhibits signs of infection or redness. It should not be applied to moles, birthmarks, or warts that have hair growing from them, nor should it be used on genital warts or warts located on the face or mucous membranes.

Patients with diabetes or those who have poor blood circulation should refrain from using this product due to the increased risk of adverse effects.

In the event that discomfort persists after application, it is advised to discontinue use and consult a healthcare professional for further evaluation.

If the product is ingested, immediate medical assistance should be sought, or contact a Poison Control Center at 1-800-222-1222 without delay.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if discomfort persists. This recommendation is crucial to ensure safety and address any potential underlying issues that may arise during treatment.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Medyi Liquid Wart Corn Remover (salicylic acid 17% liquid wart corn remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center (1-800-222-1222) should be contacted without delay.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

There is no information available regarding the use of MEDYI LIQUID WART CORN REMOVER during pregnancy, including safety concerns, dosage modifications, or any special precautions. Healthcare professionals should exercise caution when considering the use of this product in pregnant patients due to the lack of data on potential risks or fetal impacts. Women of childbearing potential should be advised to consult their healthcare provider before using this product.

Lactation

There is no information available regarding the use of MEDYI LIQUID WART CORN REMOVER in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider this lack of data when advising lactating patients.

Renal Impairment

Patients with renal impairment may not have specific dosage adjustments, special monitoring, or safety considerations outlined in the prescribing information. Therefore, healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the lack of detailed guidance necessitates careful clinical judgment and individualized patient assessment.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the prescribing information.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant regarding the potential for overdose with this medication. In cases where an overdose is suspected, immediate medical attention should be sought.

Healthcare providers are advised to monitor patients closely for any signs or symptoms that may indicate an overdose. These may include, but are not limited to, altered mental status, cardiovascular instability, or gastrointestinal disturbances.

Management of an overdose should be guided by the clinical presentation of the patient. Supportive care is paramount, and symptomatic treatment should be initiated as necessary. It is recommended that healthcare professionals consult local poison control centers or relevant toxicology resources for specific guidance on the management of overdose cases.

In summary, while no specific overdosage information is provided, healthcare professionals should be prepared to act swiftly and effectively in the event of an overdose, ensuring that appropriate measures are taken to safeguard patient health.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

Skin discoloration has been reported in postmarketing experience, occurring during or after the use of the product. These events have been documented through voluntary reports and surveillance programs.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center at 1-800-222-1222 if the product is swallowed. It is important to instruct patients not to use the product on irritated skin or on any areas that are infected or reddened. Additionally, patients should be informed to avoid application on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Those with diabetes or poor blood circulation should also be cautioned against using the product.

Patients should be instructed to discontinue use and consult a doctor if discomfort persists after application. It is essential to emphasize the importance of avoiding contact with the eyes; if the product does get into the eyes, patients should flush the area with water for 15 minutes. Providers should remind patients that the product is non-edible and should be stored with the cap tightly closed at room temperature, away from heat sources.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It should be stored at room temperature, ensuring that the temperature does not exceed 37°C (99°F) to avoid excessive heat exposure. Proper storage conditions are essential to maintain the integrity of the product.

Additional Clinical Information

The product is administered topically, with the recommended frequency of application being once or twice daily as needed until the wart is removed, for a maximum duration of 12 weeks. Clinicians should counsel patients to avoid contact with the eyes; in the event of contact, the eye should be flushed with water for 15 minutes. Additionally, if the product is ingested, patients should seek medical assistance or contact a Poison Control Center immediately at 1-800-222-1222.

Drug Information (PDF)

This file contains official product information for Medyi Liquid Wart Corn Remover, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)